ARTICLE | Company News
Calmune, Crucell deal
November 9, 2009 8:00 AM UTC
Calmune will use its SEBVI technology to generate human mAbs against an undisclosed infectious disease target for Crucell. SEBV1 technology allows high-affinity, fully human antibodies against microbi...